The European Medicines Agency (EMA) has approved the use of AIM-NASH, an artificial intelligence (AI) tool, in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Developed using machine learning, AIM-NASH was trained on over 100,000 biopsy annotations from 59 pathologists, analyzing more than 5,000 liver […]